Richard Gill, PhD
Dr. Gill has 40 years of strategic management, research, and technology commercialization experience in the life sciences industry. As the Launchpad Venture Group President and CEO of TruTouch, Dr. Gill was instrumental in garnering $9.2M of $13.5M raised to develop and commercialize the TT2500 and TTAS6000, which brought the 7-year-old alcohol and biometric company back to the workplace market in less than 4 years.
As President and CEO of ProNAI, a DNAi drug development company based in Kalamazoo, MI, Dr. Gill and his team raised $11.5M of the $13M invested to achieve an IND APPROVED lead drug product, PNT2258, in less than 2 years from the pre- IND briefing meeting with the FDA.
Dr. Gill has also served as President and CEO at Signet Laboratories, an evidence based medicine company located in Dedham, MA, for which he led a successful M&A strategy, which sold to Convance. Dr. Gill also served as President and CEO of Anvil, a preeminent commercialization partner to the life sciences industry focused on in-silico drugs discovery and drug development solutions. Prior to AnVil, Dr. Gill served as President and CEO of ActiveCyte, Newton, MA, which provided an enterprise wide solution for pharmaceutical intellectual property licensing and was sold to Wolter’s Kluwer.
Dr. Gill served as President and CEO of Genome Therapeutics Corp; now Oscient Pharmaceuticals (NASDAQ: GENE now OSCI), a Waltham, MA, genomics company, which focuses on the commercialization of genomics-based drug discovery. He had overall operational and strategic management responsibilities and led the company's successful follow on financing efforts raising $55M. Prior to this, Dr. Gill served as General Manager and Senior Vice President of BTG International, Inc., a subsidiary of BTG plc (LSE: BGC), a global leader in the patenting, marketing, and commercialization of intellectual property rights. He led the global biosciences sector of this $1.5 billion company that commercializes technology via acquisition and licensing collaborations with pharmaceutical, biotechnology, and physical sciences companies. Dr. Gill helped lead the management buyout of British Technology Group plc from the British government, the firm’s expansion into international markets, and its subsequent initial public offering. Earlier, he held positions of increasing responsibility in research and general management with Unilever plc. in the United Kingdom. Dr. Gill holds a Ph.D. in Endocrinology and a B.Sc. with honors in Physiology and Biochemistry from Reading University, UK.